Literature DB >> 3517743

Oral mucous membrane pemphigoid. A study of sixty-five patients.

S Silverman, M Gorsky, F Lozada-Nur, A Liu.   

Abstract

Sixty-five patients with oral mucous membrane pemphigoid were examined, treated, and followed for a mean of 3.5 years. Seventy-two percent were women, and the mean age was 59 years. In most patients multiple oral sites were involved and the gingiva was affected in 94% of the patients. Seven patients had ocular lesions (symblepharon), and seven others had nasal, vaginal, or pharyngeal involvement. Persons with skin lesions (bullous form) were not included in this series. Topical and systemic anti-inflammatory/immunosuppressive medications were successful in controlling signs and symptoms. There were no spontaneous remissions. Candidiasis, tobacco, other diseases, and drugs did not appear to be related to the pemphigoid.

Entities:  

Mesh:

Year:  1986        PMID: 3517743     DOI: 10.1016/0030-4220(86)90367-1

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  4 in total

1.  Oral mucous membrane pemphigoid - Two case reports with varied clinical presentation.

Authors:  Sreedevi Dharman; Arvind Muthukrishnan
Journal:  J Indian Soc Periodontol       Date:  2016 Nov-Dec

2.  Desquamative gingivitis - A clinical sign in mucous membrane pemphigoid: Report of a case and review of literature.

Authors:  Shamimul Hasan
Journal:  J Pharm Bioallied Sci       Date:  2014-04

3.  Is the 810-nm diode laser the best choice in oral soft tissue therapy?

Authors:  Nihat Akbulut; E Sebnem Kursun; M Kemal Tumer; Kivanc Kamburoglu; Ugur Gulsen
Journal:  Eur J Dent       Date:  2013-04

4.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.